nybanner

        News

        CagriSema’s clinical acceleration of weight loss in China

        On July 5, Novo Nordisk launched a phase III clinical trial of CagriSema injection in China, the purpose of which is to compare the safety and efficacy of CagriSema injection with semeglutide in obese and overweight patients in China.

        CagriSema injection is a long-acting combination therapy under development by Novo Nordisk, the main components are GLP-1 (glucagon-like peptide-1) receptor agonist smeglutide and a long-acting amylin analog cagrilintide. CagriSema injection can be administered subcutaneously once a week.

        The primary objective was to compare CagriSema (2.4 mg/2.4 mg) with semeglutide or placebo once weekly subcutaneously. Novo Nordisk has announced the results of a trial of CagriSema for the treatment of stage 2 diabetes, which proved that CagriSema's hypoglycemic effect is better than that of semeglutide, and nearly 90% of subjects have achieved the HbA1c goal.

        news11
        news12

        The data showed that in addition to the significant hypoglycemic effect, in terms of weight loss, CagriSema injection significantly outperformed semeglutide (5.1%) and cagrilintide (8.1%) with a weight loss of 15.6%.

        The innovative drug Tirzepatide is the world's first approved weekly GIP/GLP-1 receptor agonist. It combines the effects of two incretins into a single molecule that is injected once a week and is a new class of treatments for type 2 diabetes. Tirzepatide was approved by the U.S. Food and Drug Administration (FDA) in May 2022 to improve glycemic control (on a dietary basis and exercise) in adults with type 2 diabetes and is currently approved in the European Union, Japan and other countries.

        On July 5, Eli Lilly announced a phase III SURPASS-CN-MONO study on the drug clinical trial registration and information disclosure platform for the treatment of type 2 diabetes patients. SURPASS-CN-MONO is a randomized, double-blind, placebo-controlled phase III study designed to evaluate the efficacy and safety of tirzepatide monotherapy compared to placebo in people with type 2 diabetes. The study planned to include 200 patients with type 2 diabetes who were not on any antidiabetic drugs in the 90 days prior to Visit 1 (except in certain clinical situations, such as acute illness, hospitalization, or elective surgery, short-term (≤14 days) use of insulin).

        Type 2 diabetes is expected to be approved this year

        Last month, the results of a SURPASS-AP-Combo study were published May 25 in the blockbuster journal Nature Medicine. The results showed that compared with insulin glargine, Tirzepatide showed better HbA1c and weight reduction in the population of type 2 diabetes patients in the Asia-Pacific region (mainly China): HbA1c reduction of up to 2.49% and weight reduction of up to 7.2 kg (9.4%) at 40 weeks of treatment, significant improvement in blood lipids and blood pressure, and overall safety and tolerability were good.

        The Phase 3 clinical trial of SURPASS-AP-Combo is Tirzepatide's first study conducted mainly in Chinese patients with type 2 diabetes, led by Professor Ji Linong of Peking University People's Hospital. SURPASS-AP-Combo is consistent with the results of the global SURPASS series of research, which further proves that the pathophysiology of diabetes in Chinese patients is consistent with that of global patients, which is the basis for the simultaneous research and development of new drugs in China and the world, and also provides solid evidence support for giving Chinese patients the opportunity to use the latest diabetes treatment drugs and their clinical application in China as soon as possible.


        Post time: Sep-18-2023
        主站蜘蛛池模板: 国产亚洲欧美在在线人成| 好叼操这里只有精品| 亚洲第一黄色网| 被cao的合不拢腿的皇后| 国产美女网站视频| 三个黑人上我一个经过| 最近中文字幕免费mv在线视频| 健身私教弄了我好几次怎么办| 中文字幕日韩亚洲| 欧美视频第一页| 又爽又黄无遮挡高清免费视频| 国模私拍福利一区二区| 在线观看视频中文字幕| 中文字幕第四页| 最近2019中文免费字幕| 亚洲精品乱码久久久久久蜜桃图片| 美女被吸乳老师羞羞漫画| 国产毛片哪里有| 91麻豆精品国产自产在线| 青青草国产在线| 夜间禁用10大b站| 久久99国产乱子伦精品免费| 欧美午夜一区二区福利视频| 催眠医生动漫在线观看| 色多多在线视频| 天天干在线观看| 中文织田真子中文字幕| 激情内射亚洲一区二区三区爱妻| 国产一区二区三区免费在线视频 | 波多野结衣中文无毒不卡| 啊啊啊好大在线观看| 黑人巨大无码中文字幕无码| 尤果圈3.2.6破解版| 亚洲国产精品区| 色偷偷成人网免费视频男人的天堂| 国产精品一卡二卡三卡| 中文字幕无码无码专区| 极品丝袜老师h系列全文| 亚洲欧美视频在线| 秋葵视频在线观看在线下载| 国产一级做美女做受视频|